These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 498710)

  • 1. Propranolol glucuronide cumulation during long-term propranolol therapy: a proposed storage mechanism for propranolol.
    Walle T; Conradi EC; Walle UK; Fagan TC; Gaffney TE
    Clin Pharmacol Ther; 1979 Dec; 26(6):686-95. PubMed ID: 498710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol.
    Walle T; Conradi EC; Walle UK; Fagan TC; Gaffney TE
    Clin Pharmacol Ther; 1980 Jan; 27(1):22-31. PubMed ID: 7351114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presystemic and systemic glucuronidation of propranolol.
    Walle T; Fagan TC; Conradi EC; Walle UK; Gaffney TE
    Clin Pharmacol Ther; 1979 Aug; 26(2):167-72. PubMed ID: 455886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and metabolism of the pharmacologically active 4'-hydroxylated metabolite of propranolol in the dog.
    Christ DD; Walle UK; Oatis JE; Walle T
    Drug Metab Dispos; 1990; 18(1):1-4. PubMed ID: 1970766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereoselective disposition and glucuronidation of propranolol in humans.
    Silber B; Holford NH; Riegelman S
    J Pharm Sci; 1982 Jun; 71(6):699-704. PubMed ID: 7097538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic and clinical observations in cyanotic children on propranolol therapy.
    Riopel DA; Walle T
    Clin Pharmacol Ther; 1980 Dec; 28(6):743-50. PubMed ID: 7438690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of food on the intravenous and oral dose kinetics of propranolol in the dog.
    Bai SA; Walle UK; Walle T
    J Pharmacokinet Biopharm; 1985 Jun; 13(3):229-41. PubMed ID: 4087163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Propranolol, propranolol glucuronide, and naphthoxylactic acid in breast milk and plasma.
    Smith MT; Livingstone I; Hooper WD; Eadie MJ; Triggs EJ
    Ther Drug Monit; 1983; 5(1):87-93. PubMed ID: 6845404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased absorption as a possible cause for the lower bioavailability of a sustained-release propranolol.
    Takahashi H; Ogata H; Warabioka R; Kashiwada K; Ohira M; Someya K
    J Pharm Sci; 1990 Mar; 79(3):212-5. PubMed ID: 2338628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of diltiazem on the disposition and metabolism of the enantiomers of propranolol in the dog during multiple oral dosing.
    Lankford SM; Maskasame C; Bai SA
    Drug Metab Dispos; 1994; 22(5):776-87. PubMed ID: 7835231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonlinear formation of propranolol metabolites in dogs after portacaval transpositions.
    Lo MW; Pond SM; Effeney DJ; Silber BM; Riegelman S; Tozer TN
    J Pharmacokinet Biopharm; 1984 Aug; 12(4):401-12. PubMed ID: 6527232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dose and uremia on plasma and urine profiles of propranolol metabolites.
    Schneck DW; Pritchard JF; Gibson TP; Vary JE; Hayes AH
    Clin Pharmacol Ther; 1980 Jun; 27(6):744-55. PubMed ID: 7379441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct measurement of propranolol bioavailability during accumulation to steady-state.
    Wood AJ; Carr K; Vestal RE; Belcher S; Wilkinson GR; Shand DG
    Br J Clin Pharmacol; 1978 Oct; 6(4):345-50. PubMed ID: 698031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma propranolol levels in beagle dogs after administration of propranolol hemisuccinate ester.
    Garceau Y; Davis I; Hasegawa J
    J Pharm Sci; 1978 Oct; 67(10):1360-3. PubMed ID: 702279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucuronidation of propranolol by dog liver microsomes. Effects of enantiomeric inhibition and detergent treatment on stereoselectivity.
    Wilson BK; Thompson JA
    Drug Metab Dispos; 1984; 12(2):161-4. PubMed ID: 6144480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Massive propranolol metabolite retention during maintenance hemodialysis.
    Stone WJ; Walle T
    Clin Pharmacol Ther; 1980 Oct; 28(4):449-55. PubMed ID: 7408404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-dependent elimination of propranolol and its major metabolites in humans.
    Silber BM; Holford NH; Riegelman S
    J Pharm Sci; 1983 Jul; 72(7):725-32. PubMed ID: 6886977
    [No Abstract]   [Full Text] [Related]  

  • 18. [Comparative pharmacokinetic studies on the relative biologic availability of two propranolol preparations in patients with steady state essential hypertension].
    Rostock G; Faulhaber HD; Gohlke HR; Prehm C
    Pharmazie; 1986 Apr; 41(4):258-60. PubMed ID: 3725870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and metabolism of oral doses of a 4'-methylthio derivative of propranolol in man.
    Walle T; Walle UK; Cowart TD; Conradi EC; Gaffney TE
    Xenobiotica; 1990 Mar; 20(3):321-31. PubMed ID: 2336841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereospecific assay for (-)- and (+)-propranolol in human and dog plasma.
    Silber B; Riegelman S
    J Pharmacol Exp Ther; 1980 Dec; 215(3):643-8. PubMed ID: 7441523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.